Syros(SYRS)

5.14 0.15 3.006%

今开:4.98昨收:4.99
最高:5.32 最低:4.98
涨停价:0.0跌停价:0.0
总市值:1.35973E8

Syros的热门讨论

产业链观察04-09 20:31

#药闻简讯# 美国FDA已授予$Syros(SYRS)$ 他米巴罗汀与阿扎胞苷和维奈托克联合用于治疗新诊断的RARA过表达急性髓系白血病(AML)的快速通道资格。查看全文

SeekingBiotech04-09 23:04

$Syros(SYRS)$
SYRS announced that the FDA has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved test in ad...查看全文

证券出售报告

Syros(SYRS)04-03 04:25

$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000207  Act: 33  Size: 4 KB 网页链接查看全文

持股变动声明

Syros(SYRS)04-03 05:05

$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040308  Size: 12 KB 网页链接查看全文

超过5%股东持股披露「修订」

Syros(SYRS)02-14 08:05

$Syros医药(SYRS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-24-034125  Act: 34  Size: 89 KB 网页链接查看全文

超过5%股东持股披露「修订」

Syros(SYRS)02-14 08:05

$Syros医药(SYRS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-24-034118  Act: 34  Size: 100 KB 网页链接查看全文

员工持股计划

Syros(SYRS)03-27 19:05

$Syros(SYRS)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-078195  Act: 33  Size: 66 KB 网页链接查看全文

持股变动声明

Syros(SYRS)04-03 05:05

$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040320  Size: 12 KB 网页链接查看全文

其他

Syros(SYRS)04-23 19:15

$Syros(SYRS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-105892  Act: 34  Size: 556 KB 网页链接查看全文

超过5%股东持股披露

Syros(SYRS)02-15 10:05

$Syros医药(SYRS)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001140361-24-008093  Act: 34  Size: 46 KB 网页链接查看全文

1 2 3

Syros的新闻

骨髓增生性肿瘤治疗合作结束:因塞特(INCY.US)和Syros Pharmaceuticals(SYRS.US)宣布分道扬镳

智通财经APP获悉,因塞特(INCY.US)已经终止了与Syros Pharmaceuticals(SYRS.US)在骨髓增生性肿瘤治疗方面的发现和研究合作。终止协议将在8月9日起60天内生效。 2018年1月,因塞特和Syros Pharmaceuticals首次签署了一项合作协议。作为合... 网页链接

Syros的公告

其他

$Syros(SYRS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-105892  Act: 34  Size: 556 KB 网页链接

其他

$Syros(SYRS)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-105901  Act: 34  Size: 1 MB 网页链接

股东委托书协议

$Syros(SYRS)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-24-105876  Act: 34  Size: 1 MB 网页链接

其他

$Syros(SYRS)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-094755  Act: 34  Size: 1 MB 网页链接

持股变动声明

$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-042289  Size: 4 KB 网页链接

证券出售报告

$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000211  Act: 33  Size: 4 KB 网页链接

持股变动声明

$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040289  Size: 12 KB 网页链接

持股变动声明

$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040297  Size: 8 KB 网页链接

持股变动声明

$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040302  Size: 14 KB 网页链接

持股变动声明

$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040308  Size: 12 KB 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40